An FDA safety review is taking its toll on Gilenya sales. The Novartis ($NVS) multiple sclerosis pill, the first oral therapy for the debilitating disease, lost market share in January after reports that some patients died while using the drug.
The data on Rasilez 's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links...
A New Jersey jury has let Johnson & Johnson's ($JNJ) Risperdal off the hook for a patient's diabetes. But the panel determined that the company didn't do enough to warn the man's...
The Supreme Court in Pakistan has now stepped into the controversy over allegedly contaminated drugs that have killed more than 130 people and sickened hundreds more. On Monday, the court directed...
The Mediator scandal in France continues as investigators searched the offices of healthcare regulators Afssaps and the homes of several of its executives. The agency faced a public outcry over its
Poor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are
GlaxoSmithKline ($GSK) has reached a deal to settle another 20,000 lawsuits over its diabetes drug Avandia, a lawyer for the plaintiffs told Bloomberg. The settlement came out of court-ordered
European regulators are taking a closer look at Novartis' ($NVS) multiple sclerosis pill Gilenya. After the November death of a 59-year-old patient who'd just begun Gilenya therapy, triggering an FDA
A Washington couple is suing Johnson & Johnson ($JNJ) over the death of their 2-year-old son, claiming the company didn't do enough to warn patients about quality-control problems with its
The first Yaz trial won't open as scheduled. A federal judge delayed the bellwether patient lawsuit, set for trial next week, and appointed a special master to mediate instead. And this special